Cartela (Rights to Develop New Drug to Treat Osteoarthritis) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Cartela (Rights to Develop New Drug to Treat Osteoarthritis) General Information

Description

Portfolio of rights to develop an antibody-based drug to treat osteoarthritis.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Lund
  • Sweden
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Corporate Office
  • Lund
  • Sweden

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cartela (Rights to Develop New Drug to Treat Osteoarthritis) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cartela (Rights to Develop New Drug to Treat Osteoarthritis)‘s full profile, request access.

Request a free trial

Cartela (Rights to Develop New Drug to Treat Osteoarthritis) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Cartela (Rights to Develop New Drug to Treat Osteoarthritis)‘s full profile, request access.

Request a free trial

Cartela (Rights to Develop New Drug to Treat Osteoarthritis) FAQs

  • Where is Cartela (Rights to Develop New Drug to Treat Osteoarthritis) headquartered?

    Cartela (Rights to Develop New Drug to Treat Osteoarthritis) is headquartered in Lund, Sweden.

  • What industry is Cartela (Rights to Develop New Drug to Treat Osteoarthritis) in?

    Cartela (Rights to Develop New Drug to Treat Osteoarthritis)’s primary industry is Buildings and Property.

  • Is Cartela (Rights to Develop New Drug to Treat Osteoarthritis) a private or public company?

    Cartela (Rights to Develop New Drug to Treat Osteoarthritis) is a Private company.

  • What is Cartela (Rights to Develop New Drug to Treat Osteoarthritis)’s current revenue?

    The current revenue for Cartela (Rights to Develop New Drug to Treat Osteoarthritis) is .

  • Who are Cartela (Rights to Develop New Drug to Treat Osteoarthritis)’s investors?

    Cartela has invested in Cartela (Rights to Develop New Drug to Treat Osteoarthritis).

  • When was Cartela (Rights to Develop New Drug to Treat Osteoarthritis) acquired?

    Cartela (Rights to Develop New Drug to Treat Osteoarthritis) was acquired on 16-Oct-2003.

  • Who acquired Cartela (Rights to Develop New Drug to Treat Osteoarthritis)?

    Cartela (Rights to Develop New Drug to Treat Osteoarthritis) was acquired by BioInvent International.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process